S&P Futures
4,031.25 -4.50 (-0.11%) Dow Futures
32,750.00 -24.00 (-0.07%) Nasdaq Futures
12,836.25 -31.00 (-0.24%) Russell 2000 Futures
1,793.30 0.00 (0.00%) Crude Oil
69.09 -0.58 (-0.83%) Gold
1,947.70 +6.60 (+0.34%)
Stoke Therapeutics, Inc. (STOK)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.17 |
| Open | 8.21 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 8.10 - 8.41 |
| 52 Week Range | 6.88 - 24.97 |
| Volume | |
| Avg. Volume | 333,474 |
| Market Cap | 366.426M |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for STOK
Related Research
- Stoke Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 10/28/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat5 months agoArgus Research
- Zacks
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Benzinga
Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program
Stoke Therapeutics Inc (NASDAQ: STOK) announced data from a planned interim analysis of the ongoing Phase 1/2a MONARCH and ADMIRAL clinical studies of STK-001 in children and adolescents with Dravet syndrome. Today's results come almost a year after Stoke touted its first-in-human data for STK-001. In addition to positive safety, pharmacokinetic (PK) and cerebrospinal fluid (CSF) exposure data, median reductions in seizure frequency were observed among patients who were treated with multiple dos
